These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1657090)

  • 41. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers.
    Mizuno T; Nagao M; Yamada Y; Narikiyo M; Ueno M; Miyagishi M; Taira K; Nakajima Y
    Cancer Gene Ther; 2006 Feb; 13(2):131-40. PubMed ID: 16096651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy of large bowel cancer.
    Davis HL
    Cancer; 1982 Dec; 50(11 Suppl):2638-46. PubMed ID: 6215979
    [No Abstract]   [Full Text] [Related]  

  • 43. Cancers of the pancreas and hepatobiliary system.
    Sauerland C; Engelking C; Wickham R; Pearlstone DB
    Semin Oncol Nurs; 2009 Feb; 25(1):76-92. PubMed ID: 19217507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
    Rizzo A
    Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
    [No Abstract]   [Full Text] [Related]  

  • 45. Highlights of topic "Recent advances in hepato-biliary-pancreatic science".
    Fujimoto J
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):511. PubMed ID: 26100098
    [No Abstract]   [Full Text] [Related]  

  • 46. [Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Matsushiro T; Nimura Y; Nagakawa T; Nakayama T; Yamauchi H; Ogata Y; Shimada H; Miyakawa S; Yamaguchi A; Sakoda K; Yasuda H; Tsukada K; Yoshida K; Ashida H; Ishikawa Y; Kotoura Y; Kinoshita H; Kajiwara T; Watanabe G; Uchimura M; Funabiki T; Ikeda S; Okada S
    Gan To Kagaku Ryoho; 1996 May; 23(6):707-14. PubMed ID: 8645022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastrointestinal malignancies in infancy, childhood, and adolescence.
    Goldthorn JF; Canizaro PC
    Surg Clin North Am; 1986 Aug; 66(4):845-61. PubMed ID: 3738705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medical treatment of hepatocarcinoma.
    Buzzoni R; Bajetta E; Colleoni M
    Ital J Gastroenterol; 1992; 24(3):148-50. PubMed ID: 1314117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies.
    Elshami M; Ahmed FA; Hue JJ; Kakish H; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
    Surgery; 2023 Feb; 173(2):289-298. PubMed ID: 36402613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel treatments for hepatocellular cancer.
    Kerr SH; Kerr DJ
    Cancer Lett; 2009 Dec; 286(1):114-20. PubMed ID: 19664880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Liver, Pancreas, Biliary Tract New Therapeutic Strategies for Advanced Pancreatic Cancer].
    Miyazaki M
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):835-836. PubMed ID: 29066675
    [No Abstract]   [Full Text] [Related]  

  • 52. Hepatobiliary tumours.
    Simcock R
    Practitioner; 2001 Aug; 245(1625):668-74. PubMed ID: 11524939
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of cisplatin dose intensity on response and survival for patients with unresectable and untransplantable hepatocellular carcinoma: an analysis of 57 patients.
    Carr BI; Dvorchik I
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():432-5. PubMed ID: 10895191
    [No Abstract]   [Full Text] [Related]  

  • 54. [The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice].
    Uchida S; Nokita H; Horiuchi H; Hisaka T; Ishikawa H; Kawashima Y; Fujishita M; Kinoshita H; Aoyagi S; Shirouzu K
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1846-8. PubMed ID: 16315959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The neoadjuvant treatment of gastrointestinal tumors: time for rethinking?].
    Ebert MP; Schmid RM
    Dtsch Med Wochenschr; 2009 Sep; 134(37):1835-7. PubMed ID: 19728255
    [No Abstract]   [Full Text] [Related]  

  • 56. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.
    Zhang C; Kolb A; Mattern J; Gassler N; Wenger T; Herzer K; Debatin KM; Büchler M; Friess H; Rittgen W; Edler L; Herr I
    Cancer Lett; 2006 Oct; 242(1):104-11. PubMed ID: 16338063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Possibilities of immunotherapy of colorectal cancers and pancreatic tumors].
    Klapdor R
    Z Gastroenterol Verh; 1991 Mar; 26():220-7. PubMed ID: 1714155
    [No Abstract]   [Full Text] [Related]  

  • 58. Technologies for ablation of hepatocellular carcinoma.
    Callstrom MR; Charboneau JW
    Gastroenterology; 2008 Jun; 134(7):1831-5. PubMed ID: 18486619
    [No Abstract]   [Full Text] [Related]  

  • 59. Angiotensin II-induced hypertension chemotherapy (IHC) for advanced gastrointestinal, pancreatic and hepatobiliary carcinoma.
    Hoshi M; Sato H
    Intern Med; 1995 Apr; 34(4):298-9. PubMed ID: 7606107
    [No Abstract]   [Full Text] [Related]  

  • 60. Portal embolization in various types of liver: novel variables to predict hypertrophy.
    Kaido T; Arii S; Shimada Y; Mori A; Imamura M
    Hepatogastroenterology; 2003; 50(49):140-5. PubMed ID: 12630010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.